NASDAQ$NXTC

NextCure Inc · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

NextCure reported Q1 2025, a net loss of $11M, diluted EPS of ($0.39).

For Q1 2025, NextCure reported a net loss of $11M, diluted EPS was ($0.39). The filing highlights segment performance, liquidity, and management commentary on the period.

  • Net loss $11M.
  • Diluted EPS ($0.39).
  • NextCure discusses capital allocation and near-term priorities in MD&A.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.39

Previous: -$0.61+36.1%
R&D Expenses

$7.9M

No prior period
G&A Expenses

$3.7M

No prior period
Restructuring Costs

$0.00

No prior period
Capital Expenditures

$0.00

Previous: -$37K+100.0%
Net Income

-$11M

Previous: -$17.1M+35.8%
Operating Income

-$11.6M

Previous: -$18.3M+36.6%
Gross Profit

-$654K

Previous: -$940K+30.4%
R&D Expense

$7.9M

Previous: $11.4M-30.7%

Revenue & EPS history

NextCure · Revenue · Quarterly

$0

Q1 2025

Forward guidance

Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.

Tailwinds

  • Headline results and segment trends anchor the quarter.
  • Liquidity and balance-sheet capacity support operations.
  • Strategic initiatives outlined in MD&A.

Headwinds

  • Macro, rates, or input costs may pressure margins.
  • One-time items affect year-over-year comparability.
  • Execution risk on growth or restructuring plans.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

+0.7%

Avg return

Earnings day

+1.0%

Avg return

5 days after

-1.4%

Avg return

30 days after

36%

10 / 28 earnings

Positive

+34.8%

Q4 2023

Best reaction

-19.8%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.9%+6.6%-16.0%
Q3 2025-8.8%-5.4%+25.6%
Q2 2025-4.4%+1.9%-4.8%
Q2 2024-1.2%+1.9%-4.8%
Q1 2025-7.7%-20.8%+2.5%
Q4 2024+6.1%-1.7%-37.7%
Q3 2024-1.5%+18.0%-12.6%
Q1 2024+11.7%+15.3%+12.4%
Q4 2023+34.8%+39.7%+13.5%
Q3 2023+10.3%+6.5%+12.1%
Q2 2023-2.9%-2.3%-18.9%
Q1 2023+4.6%+14.5%+14.5%
Q4 2022-4.5%-5.1%-5.7%
Q3 2022-19.8%-31.2%-42.9%
Q2 2022+9.8%+14.0%-5.1%
Q1 2022-4.5%-15.1%+4.8%
Q4 2021-1.4%+0.4%+2.7%
Q3 2021-1.4%-23.5%-34.5%
Q2 2021+5.8%+3.2%+7.5%
Q1 2021+3.4%+5.0%-1.0%
Q4 2020-2.0%+2.1%-12.7%
Q3 2020-4.3%+0.9%+11.0%
Q2 2020-1.3%-3.1%-14.2%
Q1 2020+12.2%+4.0%-24.8%
Q4 2019-12.3%+4.0%+5.2%
Q3 2019-3.3%-7.6%+31.3%
Q2 2019+11.7%+11.1%+53.9%
Q1 2019-6.8%-6.3%+0.5%
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro